{"id":"NCT03823300","sponsor":"Hoffmann-La Roche","briefTitle":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)","officialTitle":"A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-11","primaryCompletion":"2020-10-05","completion":"2022-01-07","firstPosted":"2019-01-30","resultsPosted":"2022-05-04","lastUpdate":"2025-07-11"},"enrollment":658,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Wet Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Faricimab","otherNames":["VABYSMO™","RO6867461","RG7716"]},{"type":"DRUG","name":"Aflibercept","otherNames":["Eylea"]},{"type":"PROCEDURE","name":"Sham Procedure","otherNames":[]}],"arms":[{"label":"Arm A: Faricimab","type":"EXPERIMENTAL"},{"label":"Arm B: Aflibercept","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).","primaryOutcome":{"measure":"Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48","timeFrame":"From Baseline through Week 48","effectByArm":[{"arm":"Arm A: Faricimab","deltaMin":6.6,"sd":null},{"arm":"Arm B: Aflibercept","deltaMin":6.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":137,"countries":["United States","Argentina","Australia","Austria","Brazil","Bulgaria","China","Denmark","France","Germany","Hong Kong","Hungary","Italy","Poland","Portugal","Russia","Singapore","South Korea","Spain","Taiwan","Turkey (Türkiye)"]},"refs":{"pmids":["38382813","37294433","36246941","35085502"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":331},"commonTop":["Neovascular age-related macular degeneration","Conjunctival haemorrhage","Cataract","Nasopharyngitis","Urinary tract infection"]}}